First-Line Treatment with Encorafenib Plus Cetuximab Plus mFOLFOX6 Significantly Improves ORR in Patients with BRAF V600E-mutated mCRC By Ogkologos - February 17, 2025 743 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment... March 14, 2023 FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy March 16, 2023 ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... August 14, 2025 Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... October 15, 2025 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Zanidatamab FDA Approves Pralsetinib for Non-Small Cell Lung Cancer with RET Gene... Potential for Larger Gene Panels to Increase the Number of Molecularly... New study to investigate breast cancer in ethnic minority groups
